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Purpose: Autologous veins used as arterial bypass grafts undergo initial loss of the 
endothelial cell (EC) lining, which is followed by reendothelialization. Wecharacterized 
the expression of the EC-specific angiogeuic mitogen, vascular endothelial growth factor 
(VEGF), in vascular grafts to help elucidate the molecular and cellular events after bypass 
procedures. 
Methods: Cephalic vein-femoral rtery interposition grafts were placed in mongrel dogs. 
Vein grafts and arteries were harvested at either 48 hours or 4 weeks after bypass, the 
total RNA was isolated, and the VEGF mRNA expression was evaluated by Northern 
blot analysis. Tissue segments from each time period were evaluated by immunohisto- 
chemical analysis using anti-VEGF antibodies. 
Results: VEGF mRNA expression in vein grafts as compared with control veins was 
increased 2.5-fold 48 hours after bypass grafting (p = 0.02) but returned to initial 
control evels in grafts removed at 4 weeks. Distal arterial segments, which included the 
anastomotic site without attached vein graft, had a 21.4-fold increase in VEGF expres- 
sion at 48 hours (p = 0.02) and a 6.6-fold increase at 4 weeks (p < 0.01) as compared 
with control arterial segments. Vessels subjected to arteriotomy or ischemia lone also 
demonstrated increased VEGF expression. Immunohistochemical analysis revealed 
VEGF protein within ECs and smooth muscle cells of the venous bypass graft, with 
maximal levels observed within intimal hyperplasia at the arterial anastomosis. 
Conclusions: After arterial reconstruction procedures using venous conduits, VEGF is 
significantly increased at 48 hours in the vein graft and arterial anastomosis. VEGF 
expression i  the vein graft normalizes within 4 weeks but remains ignificantly elevated 
in the adjacent arterial segment. Increased VEGF production after arterial grafting may 
facilitate reendothelialization, thus partially accounting for optimal patency rates 
achieved with autologous vein grafts. (J Vasc Surg 1997;26:79-86.) 
Vascular endothelial growth factor (VEGF) is a ho- 
modimeric glycoprotein produced by many different 
cell types both in culture and in vivo. 1,2 Because of 
high affinity receptors expressed ahnost exclusively 
on endothelial cells (ECs), VEGF is an EC-specific 
mitogen. ~,a,4 VEGF has structural similarity to plate- 
let-derived growth factor (PDGF), 5 and, although it 
is encoded on a single gene, four different isoforms 
can arise from differential messenger RNA (mRNA) 
splicing. 6 A role for VEGF has been implicated in 
pathologic angiogenic conditions such as tumor 
growth 7,8 and diabetic retinopathy, 9,1° as well as in 
the normal development of the vasculature. 11,12 
In cell culture, VEGF expression can be increased 
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by several mechanisms, including stimulation by 
growth factors (basic fibroblast growth factor 
[bFGF], 13 transforming growth factor-J3 [TGF-[3], 14 
PDGF 14) and cytokines (tumor necrosis factor-c~, 
interleuldn-l-[3s). VEGF mRNA expression is also 
increased by hypoxia in numerous cell lines, includ- 
ing ECs and vascular smooth muscle cells 
(VSMCs) .  2,8,14 In addition, PDGF and bFGF have 
synergistic effects on the induction of VEGF at mod- 
erate levels of hypoxia in VSMCs? 3,15 The hypoxic 
induction of VEGF has previously been postulated to 
account for sustaining angiogenesis in tumor growth 
and in the induction ofischemic retinopathies such as 
diabetic retinopathy and central retinal vein occlusion. 9 
Recent data have shown that VEGF infused in- 
traarterially improves the collateral flow in a hind- 
limb model ofischemia 16 and mitigates the develop- 
ment of intimal hyperplasia observed after balloon 
catheter-induced arterial injury. 17 The beneficial ef- 
fect of VEGF after balloon denudation i jury appears 
to result primarily from an earlier, more extensive, 
and more histologically normal reendothelialization 
of the vessel. Those portions of the vessel that were 
repopulated by ECs had little or no neoiutimal 
growth. 17 Indeed, the so-called protective ffect of 
an intact endothelium has led to attempts to seed 
prosthetic grafts with ECs before their implantation 
into arterial circuits? s 
Arterial grafts using autologous vein as conduits 
are extremely common, being used for coronary, 
femoral, and tibial artery ischemia. They have been 
clearly demonstrated to have a superior patency rate 
when compared with prosthetic onduits in almost 
every circumstance? 9 Although they provide an 
overall better conduit, they still may suffer the same 
problems as their prosthetic ounterparts, namely, 
development of neointimal hyperplasia nd ulti- 
mately restenosis. After placement of a vein in an 
arterial circuit, "arterialization" occurs over the 
course of weeks. Initially, there is loss of the EC 
lining comprising the intima, followed by polymor- 
phonuclear cell and macrophage infiltration. The 
vein wall becomes thickened and edematous. Over 
the course of the first week the endothelium is re- 
stored, but the vein wall is further thickened with a 
neointima of variable size. This neointima continues 
to increase in thiclmess and can lead to restenosis at 
any point along the conduit. 2°,2~ Recently, evalua- 
tion of growth factor expression in veins used as 
bypass conduits revealed a prolonged upregulation 
of TGF-[3 and a more transient increase in PDGF. 21 
To date, VEGF expression has not been evaluated in
this context. 
Numerous studies have demonstrated that 
VSMCs play a significant role in the development of
neointimal lesions regardless of whether they de- 
velop after angioplasty, after vein bypass grating, or 
after prosthetic grafting. 22-26 VSMCs are known to 
express VEGF mRNA, 3 although there is no evi- 
dence that they can respond to this growth factor. 
However, it is probable that VSMCs, exposed to 
conditions uch as hypoxia or diffusible factors such 
as bFGF or PDGF, may act as a source of VEGF that 
may then function in a paracrine manner. To date 
there are no studies that evaluate the expression of 
VEGF in veins at baseline and when used as arterial 
conduits. I f  VEGF is expressed in this scenario, an 
increase might play a role in maintaining and repair- 
ing the integrity of the endothelium after damages. 
To investigate and follow the expression of VEGF of 
vein grafts, we used a canine cephalic vein-femoral 
artery interposition graft model. The dog model was 
chosen because of its similarity both in failure pat- 
terns and in "healing" to human grafts. 27 This is the 
first report to document he expression of VEGF 
after bypass grafting. 
MATERIALS AND METHODS 
Eight mongrel dogs weighing 20 to 25 kg were used. 
Animal care complied with the "Principles of Labo- 
ratory Animal Care" (formulated by the National 
Society for Medical Research) and the Guide for the 
Care and Use of Laboratory Animals (NIH Publica- 
tion No. 86-23, revised 1985). 32P-dATP, which has 
a specific activity of 3000 Ci/mmol, was obtained 
from DuPont/NEN. 
Procedure. General anesthesia was established 
after the dogs were sedated with acepromazine (0.75 
mg/kg subcutaneously) and an intravenous infusion 
of pentobarbital (10 to 12 mg/kg),  and was main- 
tained with endotracheal-tube inhalation of halo- 
thane. Briefly, the right femoral artery was isolated, 
and vascular control was obtained proximally and 
distally. Cephalic veins were isolated bilaterally. Both 
veins were lightly distended with saline solution, and 
one vein was chosen as the bypass conduit. The other 
vein was immediately snap-frozen i  liquid nitrogen 
to serve as a control specimen. Systemic heparin was 
infused before creation of the anastomoses. End-to- 
side anastomoses were created on the reversed vein 
with 7-0 prolene sutures. The intervening segment 
of femoral artery was then ligated, creating preferen- 
tial flow through the graft and establishing a func- 
tional end-end anastomosis (Fig. 1). After hemosta- 
sis was achieved, the wounds were closed in several 
layers with 3-0 vicryl sutures. The patency of the 
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Fig. 1. Diagram depicts vein bypass graft in canine model. At time of harvesting, bypass grafts 
were disconnected from anastomotic sites to isolate specific areas for VEGF mRNA expression 
determination. 
graft was established through direct palpation and 
Doppler examination. Early (48 hours) and late (4 
weeks) time intervals were chosen for investigation, 
and three animals were entered into each group be- 
fore surgery. Harvest of specimens was performed 
with the dog under general anesthesia as delineated 
above. The vein bypass graft was separated totally 
from the distal femoral artery and anastomosis sothat 
the venous and arterial tissues were not mixed to- 
gether in the specimens. These two segments, as well 
as the contralateral femoral artery that did not un- 
dergo a procedure, were all snap-frozen in liquid 
nitrogen. Representative portions were retained for 
histologic analysis. One animal in the 4-week bypass 
group developed a superficial wound infection, so all 
RNA obtained from this dog, except he control vein 
taken at the time of initial operation (and thus before 
infection), was excluded. All bypass grafts were 
patent at the time of harvest. 
To control for the possible effects of the surgical 
intervention itself on the VEGF expression and to 
evaluate whether expression was different at the 
proximal and distal anastomoses, anadditional oper- 
ation was performed. Proximal and distal arterioto- 
mies were made in the left femoral artery and then 
closed with 7-0 prolene. Ischemic time produced by 
vascular loops approximated that seen in the bypass 
model. A cephalic vein interposition graft was placed 
on the right as described previously. After 48 hours, 
the arterial portions of the proximal and distal anas- 
tomoses and proximal and distal arteriotomies were 
harvested separately and sectioned away from the 
remaining vessel. An additional separate xperiment 
was performed in which arteriotomies were per- 
formed on one femoral artery as above. On the other 
femoral artery, the vessel was isolated as in all previ- 
ous operations and vascular loops were passed proxi- 
mally and distally. The loops were then occluded for 
the identical time period as the contralateral rtery. 
The vessel was then allowed to reperfuse. No inci- 
sions or other procedures were performed on this 
(hypoxia nd reperfusion alone) vessel. Both the hy- 
poxic vessel and the vessel with the arteriotomies 
were harvested at 48 hours. 
Northern blot analysis. Total RNA was iso- 
lated from the tissue specimens with use of the acid- 
guanidium-thiocyanate technique and phenobchlo- 
roform extraction. 28The unoperated cephalic vein 
was used as a control for the bypassed vein, and the 
contralateral unoperated artery was used as a control 
for the arterial segment at the distal anastomosis. 
Radioactive VEGF probes were generated using Am- 
crsham Multiprime labeling kits (Arlington Heights, 
Ill.), human VEGF cDNA (provided by Lloyd P. 
Aiello, MD, PhD), 2,4,9 and 32p-ATP. Northern blot 
analysis was performed on 20 btg total RNA with use 
of formaldehyde denaturing gel electrophoresis, 
transfer to ICN Biochemicals (Irvine, Calif.). Bio- 
trans nylon membranes and ultraviolet cross-linking 
using a Stratagenc UV Stratalinker 2400 with an 
intensity of 1200 btJ × 100 (LaJolla, Calif.). Blots 
were prehybridized and hybridized (1 × 106 cpm/  
ml) per manufacturer instructions. Signals were ana- 
lyzed using a Molecular Dynamics PhosphorImager. 
Lane loading differences were normalized by rehy- 
bridizing to a constitutively expressed mRNA using 
36B4 cDNA probe on the same blots. 29-31 
Histologic/immunohistochemical analysis. 
Selected sections were processed through graded 
ethanols and were embedded in paraffin. Five-mi- 
crometer sections were cut and stained with hema- 
toxylin and eosin. Sections were deparaffinized in
xylenes and rehydrated to water. Microwave antigen 
retrieval was performed for 30 minutes in citrate 
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Fig. 2. Northern blot analysis of VEGF mRNA expres- 
sion in cephalic vein-femoral rtery bypass grafts. A, Forty- 
eight hours after grafting, total RNA was isolated from 
control artery (A), control vein (V), vein bypass graft (B), 
and distal arterial anastomosis (An)as indicated. All RNA 
was harvested from the same animal. B, Four weeks after 
grafting, total RNA was isolated from control artery (A), 
control vein (V), vein bypass graft (B), and distal arterial 
anastomosis (An) as indicated. All RNA was harvested 
from an additional animal. Northern blot analysis was per- 
formed on both blots using a a2p-labeled cDNA probe for 
VEGF, detected at 4.3 KB. The blots were stripped and 
rehybridized with a cDNA probe for 36B4, detected at 1.6 
KB, to compare lane loading. 
buffer before application of primary antibody. Sec- 
tions were coated with serum-free protein block 
(DM(O) for 10 minutes followed by phosphate buff- 
ered saline solution (PBS) washes. Anti-VEGF anti- 
body (R&D Systems) was applied to sections in a 
1:100 dilution and incubated at 4 ° C overnight. Af- 
ter three PBS rinses, secondary antibody (universal 
immunoglobulin G, DM(O) was applied for 30 min- 
utes. Streptavidin peroxidase was incubated on the 
sections for 30 minutes, rinsed with PBS, and sec- 
tions were developed using 3'amino 9'ethyl carba- 
zole. Sections were counterstained in hematoxylin 
before application of the cover slip. Positive control 
analyses were performed using granulation tissue, 
establishing specificity of the antibody and appropri- 
ate titers to be used for the test tissues. Negative 
control analyses were performed under the same 
conditions omitting the primary antibody. Red- 
brown coloration indicated anti-VEGF antibody 
binding to VEGF protein, except in white blood ceils 
where endogenous peroxidase activity is present. En- 
dogenous peroxidase activity was quenched using 3% 
hydrogen peroxide. 
Statistical analysis. Results are expressed as 
mean _+ standard error for all experimental points. 
Statistical comparison used Student's unpaired t test 
for data with normal distributions and the Mann- 
Whitney rank sum test for quantitating data with 
unequal variance. 
RESULTS 
VEGF expression in vein bypass grafts and 
arterial anastomoses in vivo. Femoral artery bypass 
grafts using autogenous cephalic vein as a conduit 
were harvested at either 48 hours or 4 weeks depend- 
ing on the interval determined before surgery. M1 
VEGF mRNA expression was normalized to the ex- 
pression of 36B4 (a constitutively regulated mRNA 
that served as a measure of total RNA loading) and 
was expressed as change from control. 
Baseline VEGF mRNA expression was low in the 
control femoral artery (n = 5) that was not surgically 
manipulated and was 5.1-fold higher in the control 
cephalic vein (p < 0.01; n = 7; Fig. 2, A and Fig. 3). 
Forty-eight hours after grafting expression in the 
venous bypass conduit itself (n = 3) was increased 
2.5-fold (20 = 0.02) as compared with the expression 
in the control vein (n = 7) and 12.7-fold elevated as 
compared with control artery (n = 5; p < 0.01; Fig. 
2, A and Fig. 3). However, in bypass grafts left intact 
for 4 weeks (n = 2), VEGF expression had returned 
to the venous baseline level (Fig. 2, B and Fig. 3). 
When artery comprising the distal anastomosis and a 
5 cm portion of the downstream vessel was evaluated 
at 48 hours (n = 3), a 21.4-fold increase in VEGF 
mRNA expression compared with baseline artery was 
observed (p = 0.02; Fig. 2, A and Fig. 3). This 
increase in VEGF expression had diminished when 
the same sections were evaluated after 4 weeks (n = 
3), but was still significantly elevated by 6.6-fold (p < 
0.01; Fig. 2, B and Fig. 3). Induction of VEGF 
expression i  the distal arterial segment was not spe- 
cific to the downstream anastomosis because a similar 
large increase in VEGF expression at 48 hours was 
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noted in a 5 cm arterial segment comprising the 
proximal anastomosis (data not shown). 
VEGF expression in vessels subjected to arte- 
r iotomy or ischemia. Arteriotomy and suture re- 
pair of the femoral artery alone, without a venous 
bypass, also resulted in a large increase in VEGF 
mRNA expression. In the single animal studied, after 
48 hours the magnitude of this response was 71% of 
that observed at the distal arterial anastomosis after 
vein bypass. In the artery that was subjected only to 
ischemia nd reperfusion, elevated VEGF expression 
was noted in segments that were distal to the vascular 
loops (and thus were ischemic) for 1 hour. The 
magnitude of this induction was approximately 85% 
of that observed after arteriotomy or 60% of that 
observed at the distal arterial anastomosis after vein 
bypass grafting. Segments that were proximal to the 
region of ischemia did not demonstrate he altered 
VEGF expression. As stated before, a large increase 
was noted in the segments 5 cm downstream from 
the arterial injury caused by either grafting or arteri- 
otomy. However, in arterial segments 5 cm upstream 
from the either the proximal anastomosis or proximal 
arteriotomy, minimal increases in VEGF mRNA 
were noted. 
Immunohistochemical  analysis of  VEGF pro- 
tein expression. Immunohistochemical analysis us- 
ing anti-VEGF antibody demonstrated intense stain- 
ing throughout the vein graft wall at 48 hours (which 
indicates increased VEGF protein levels), which was 
not observed in the control veins or arteries (Fig. 4). 
In the 4 week sample at the arterial portion of the 
distal anastomosis, there was a significant amount of 
smooth muscle cell proliferation above the arterial 
internal elastic lamina. Throughout this hyperplastic 
segment, here was bright VEGF staining that could 
also be seen within the underlying smooth muscle 
cells of the arterial wall (Fig. 5). This staining pattern 
correlated closely with the VEGF mRNA expression 
observed by Northern blot analysis. 
D ISCUSSION 
In thisj report, we demonstrate that VEGF mRNA 
expression is significantly increased 48 hours after 
cephalic vein-femoral artery bypass grafting in both 
the vein graft and in the arterial anastomoses. By 4 
weeks after grafting, VEGF expression i  the venous 
bypass conduit itself had returned to baseline levels 
but was still significantly elevated in the arterial seg- 
ment comprising the distal anastomosis. Although 
VEGF elevation was similar at both the proximal and 
distal anastomoses, the remote increase in VEGF 
expression was predominantly observed in the down- 
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Fig. 3. Quantitafion of VEGF mRNA expression in ce- 
phalic vein-femoral artery bypass grafts. VEGF mRNA 
expression was visualized and quanfitated using a phos- 
phorimager. Lane loading was normalized to 36B4 expres- 
sion on same blots, and values are expressed as arbitrary 
units (mean -+ SEM) for multiple experiments. Under the 
heading ARTERY the data represented are as follows: 
control artery (CON), n = 5; arterial anastomosis 48 hours 
after grafting (48HR), n = 3; and arterial anastomosis 4 
weeks after grafting (4W), n = 3. Under the heading 
VEIN the data represented are as follows: control vein 
(CON), n = 7; vein bypass at 48 hrs (48HR), n = 3; and 
vein bypass at 4 weeks (4W), n = 2. 
stream vessel, with only a nonsignificant increase in 
VEGF expression observed in artery upstream from the 
proximal anastomosis. All observed increases ha VEGF 
mRNA were confirmed at the protein level using anti- 
VEGF antibody and immunohistochemical analysis. 
When a vein is used as an arterial conduit, numer- 
ous changes occur, including initial EC loss and 
recovery, wall thickening, and development ofa vari- 
able layer of neointima. 2°,21 In addition, when the 
vein is taken out of its in situ position and grafted, it 
invariably suffers some hypoxic stress. Hypoxia has 
been shown in numerous tudies to induce VEGF 
expression i  vascular cells. 8 This hypoxic stress may 
partially account for the induction seen at 48 hours 
in the vein graft itself. That VEGF was induced at the 
point when ECs are lost and then start to repopulate 
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Fig. 4. Immunohistochemical an lysis of a vein bypass graft 48 hours after arterial reconstruc- 
tion. Intense staining with VEGF antibody (red-brown color) is observed throughout the graft 
wall, corresponding to the smooth muscle cells. Some staining s also evident in white cells that 
have endogenous peroxidase activity. 
the graft suggests that VEGF plays a role in promot- 
ing the reendothelialization process. Because xoge- 
nous VEGF has been shown to increase reendotheli- 
alization after balloon-catheter denudation i juries, 17 
one may speculate that the response seen naturally 
after venous grafting could be augmented by addi- 
tion of exogenous VEGF. The finding that VEGF 
expression in vein grafts had returned to baseline 
after 4 weeks may be a result of the now complete 
repopulation of the wall with ECs. 
The increase in VEGF expression at the distal 
artery observed at both 48 hours and 4 weeks (21.4- 
fold and 6.6-fold respectively) was surprising, both in 
magnitude and duration. That VEGF expression in 
the control artery is less than 20% of the levels in 
control vein partially accounts for the larger total 
increase over baseline in the distal artery. However, 
the maximum levels of expression i  the venous by- 
pass (48 hours) were only two thirds of the maximal 
expression observed in the distal artery (48 hours). 
To better define the possible cause of this VEGF 
induction, we examined an artery that was subjected 
to an arteriotomy and suture repair, without graft 
placement. There was a significant increase in expres- 
sion (arteriotomy alone), although the magnitude 
was less than that seen in the artery after graft place- 
ment, suggesting that both arterial wall injury and 
changes related to graft placement contribute to 
VEGF induction. Also, while the vein graft was being 
placed, the artery encompassed in the vascular loops 
experienced ischemic/hypoxic stress. This hypoxic 
stress may account for a large portion of the early 
induction of VEGF in the arterial anastomosis be- 
cause, in the artery subjected to i hour of ischemia 
without any direct arterial injury, VEGF expression 
increased almost o the levels observed after arteriot- 
omy alone. Reperfusion injury may also play a role 
here. Indeed, in coronary arteries tudied after occlu- 
sion and then reperfusion with a mammary artery 
bypass, EC swelling, separation ofintercelhilar junc- 
tions, and areas of extensive denudation were not- 
ed. 32 It thus appears that multiple concurrent, inter- 
acting mechanisms are involved in induction of 
VEGF and that increased VEGF expression may rep- 
resent a protective mechanism of vessels after various 
types of injury. 
Hypoxia is unlikely to be the mechanism for the 
apparently chronic induction of VEGF expression i  
the distal artery, still apparent at 4 weeks, because the 
distal vessel does not remain hypoxic for this entire 
period. It is likely that additional factors may be 
involved. PDGF, bFGF, and TGF-[3 have been dem- 
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Fig. 5. Immunohistochemical analysis of anastomotic arterial segment 4 weeks after arterial 
reconstruction. There is obvious proliferation of cells above arterial internal elastic lamina 
(arrows). VEGF antibody staining is seen within hyperplastic smooth muscle cells as well as 
within smooth muscle cells on underlying native arterial wall. 
onstrated to induce VEGF expression 13,~4 and are 
stimulated after arterial injury and vascular graft- 
ing. 21,33 Both bFGF and PDGF reveal synergism 
with hypoxia in increasing VEGF expression) 3,~s 
Clearly, these growth factors could also be involved 
in the early VEGF inductions in the artery and ve- 
nous bypass. It remains to be seen whethcr alteration 
in flow dynamics and shear stress at the distal anasto- 
mosis or other mechanisms can induce or maintain 
the chronic elevation in VEGF expression. It is pos- 
sible that VEGF expression is maintained in the ar- 
tery but not in the venous bypass as a result of the 
larger density of VSMCs, which, when exposed to 
hypoxia nd numerous growth factors and cytokines, 
may respond in a continued paracrine fashion. In- 
deed, smooth muscle cells within areas of intimal 
hyperplasia t the distal arterial anastomosis ex- 
pressed high levels of VEGF compared with smooth 
muscle ceils of the native arterial media. That VEGF 
expression is essentially unaltered in artery upstream 
from either the arteriotomy alone or the proximal 
anastomosis suggests that the induction in the distal 
artery is either caused by factors that are secreted into 
the blood stream that act distally or that only seg- 
ments that experience some ischemia nd reperfusion 
increase VEGF expression. 
Finally, it is interesting to note that pcripheral 
veins have over five times greater expression of VEGF 
than peripheral artery, suggesting that the relatively 
chronic venous hypoxia may regulate VEGF ex- 
pression in vessels in vivo. It is possible that after a 
longer time in the arterial circuit, the level of  
VEGF expression i  the bypassed vein may actually 
decrease to near the level seen in the control ar- 
tery. However, further studies are needed to eval- 
uate this possibility. 
CONCLUSION 
These data represent the first evidence of elevated 
VEGF mRNA expression after arterial bypass graft- 
ing using autologous vein. We have demonstrated an
early increase in VEGF mRNA expression in the 
venous grafts, possibly as a result of stimulation from 
hypoxia or growth factor elaboration. This response 
may help to promote the reendothelialization of the 
venous conduit, a phenomenon that does not occur 
in human or canine prosthetic-arterial conduits and 
that may help to explain the superior patency rates of 
autologous vein grafts. In addition, the larger and 
persistent increase in VEGF expression observed in 
the distal artery suggests involvement of other mech- 
anisms of in vivo ~ vascular VEGF regulation. 
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